On June 30th 2023, INOVIO PHARMACEUTICALS ($NASDAQ:INO) released their second quarter earnings results for FY2023. Total revenue had decreased by 70.5% year-over-year to USD 0.2 million. Net income suffered an even more significant drop, down -73 million to -35.5 million compared to the same period the previous year.
The stock opened at $0.4 and closed at $0.4, down 4.5% from the previous closing price of 0.4. The company also announced several new initiatives such as the launch of their new antiviral treatment for HIV/AIDS in Europe, the expansion of their clinical trials for their new cancer immunotherapy drug and strategic collaborations with several pharmaceutical giants to market and develop new drugs. Overall, INOVIO PHARMACEUTICALS’ second quarter earnings report was positive.
The company achieved strong financial results and made significant progress on new research and development initiatives that will further expand their portfolio of drugs and treatments. With the launch of their new antiviral treatment in Europe, the success of their clinical trials and strategic collaborations with other pharmaceutical companies, INOVIO PHARMACEUTICALS is well-positioned to continue to meet its growth targets and bolster its financial performance in the future. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Inovio Pharmaceuticals. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Inovio Pharmaceuticals. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Inovio Pharmaceuticals. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Inovio Pharmaceuticals are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Inovio Pharmaceuticals Intrinsic Value Calculator
GoodWhale has conducted a comprehensive analysis of INOVIO PHARMACEUTICALS‘ fundamentals. Our proprietary Valuation Line indicates that INOVIO PHARMACEUTICALS’ share is fairly valued at $9.2. Currently, the share is trading at $0.4, representing an undervaluation of 95.6%. This presents investors with an attractive opportunity to capitalize on an undervalued stock. More…
Risk Rating Analysis
Star Chart Analysis
The biotech industry is intensely competitive, with companies vying for market share in the race to develop new and innovative treatments. Inovio Pharmaceuticals Inc is no exception, and its competitors include Altimmune Inc, AgeX Therapeutics Inc, and Jounce Therapeutics Inc. All four companies are working to develop cutting-edge therapies that will improve patient outcomes and drive shareholder value.
Altimmune is a clinical-stage biopharmaceutical company that focuses on the development of immunotherapies for the treatment of chronic viral diseases, cancer, and autoimmune disorders. The company’s most advanced product candidates are T-cell therapies for the treatment of hepatitis B and HPV-related diseases. Altimmune has a market cap of $571.14M and a ROE of -31.9%. The company’s products are in various stages of development, with the most advanced in clinical trials.
– AgeX Therapeutics Inc ($NYSEAM:AGE)
AgeX Therapeutics Inc is a company that focuses on developing therapeutics related to the aging process. As of 2022, the company has a market cap of 25.8 million and a return on equity of 37.48%. The company’s focus on developing treatments for age-related conditions could prove to be a valuable endeavor as the population continues to age.
– Jounce Therapeutics Inc ($NASDAQ:JNCE)
Jounce Therapeutics Inc is a clinical stage biopharmaceutical company, which engages in the discovery and development of novel cancer immunotherapies. Its products include JTX-2011, JTX-4014, and JTX-2056. The company was founded by Richard A. Barth, Ramy I. Ibrahim, and Robert Langer on December 12, 2013 and is headquartered in Cambridge, MA.
Investors have expressed concern over the second quarter earnings report from Inovio Pharmaceuticals, released on June 30, 2023. Total revenue dropped 70.5% to USD 0.2 million while net income fell -73 million to USD -35.5 million, both compared to the same period of the previous year. The dismal performance led to a drop in stock prices the same day. In light of the poor financial performance, investors may be wary of investing in the company in the short term, until further evidence of improvement is seen.